Print Email

About Study Groups  |  Study Groups  |  Workshops  |  Surveys  |  Resources

MASCC Nutrition and Cachexia Study Group

Leadership

Chair: Liz Isenring, PhD (e.isenring@uq.edu.au)  - Australia
Vice-Chair: Florian Strasser, MD, ABHPM (fstrasser@bluewin.ch) - Switzerland

Objective

The MASCC Nutrition Study Group encourages broad-based research and state-of-the-art clinical practice in all areas of clinical nutrition as it relates to cancer.

Goals

A major goal of this Study Group is to increase awareness of existing guidelines for the appropriate use of nutritional support in cancer patients. It also aims to promote appropriate use of palliative and therapeutic strategies in the management of anorexia and weight loss in patients with advanced cancer. The group works to develop and coordinate new evidence-based guidelines. The Study Group encourages research in areas where scientific literature is lacking with the goal of improving the current state of clinical practice. The use of nutrition-based complementary and alternative medicine therapies remains a focus of this group, and the group encourages research and guideline development on emerging, related issues, as appropriate. As a subgroup of a large international organization, the MASCC Nutrition and Cachexia Study Group remains sensitive in all its endeavors to the cultural and economic differences in cancer populations around the world.

In summary, the MASCC Nutrition Study Group serves as a resource for the development of both clinical and laboratory research and for the development of clinical practice guidelines relevant to all aspects of clinical nutrition in relation to cancer.

Past Workshops

Survey

Attitudes, Beliefs, and Behaviors of Healthcare Professionals Regarding Dietary Supplements
"Do you recommend dietary supplements to your patients? Do you use them yourself? Professor Liz Isenring, chair of the MASCC Nutrition and Cachexia group is conducting an anonymous survey on the attitudes, beliefs, and behaviors of healthcare professionals regarding dietary supplements. If you consult directly with patients, we would like to invite you to contribute to our survey by clicking on the link below. It should take no longer than 10 minutes and has been approved by the Bond University (Australia) ethics committee. Your input would be greatly appreciated!"  >> Proceed to Survey  11.20.14

Recent Publications

Thamsborg LH, Petersen MA, Aaronson NK, Chie WC, Costantini A, Holzner B, Verdonck-de Leeuw IM, Young T, Groenvold M; EORTC Quality of Life Group. Development of a lack of appetite item bank for computer-adaptive testing (CAT). Support Care Cancer. 2015 Jun;23(6):1541-8.

Isenring E, Elia M. Which screening method is appropriate for older cancer patients at risk for malnutrition? Nutrition. 2015 Apr;31(4):594-7.

Vivanti A, Isenring E, Baumann S, Powrie D, O'Neill M, Clark D, Courtice S, Campbell K, Ferguson M. Emergency department malnutrition screening and support model improves outcomes in a pilot randomised controlled trial. Emerg Med J. 2015 Mar;32(3):180-3.

Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, Strasser F, Thoresen L, Jagoe RT, Chasen M, Lundholm K, Bosaeus I, Fearon KH, Baracos VE. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2015 Jan 1;33(1):90-9. Erratum in: J Clin Oncol. 2015 Mar 1;33(7):814.

Blum D, Rosa D, deWolf-Linder S, Hayoz S, Ribi K, Koeberle D, Strasser F. Development and validation of a medical chart review checklist for symptom management performance of oncologists in the routine care of patients with advanced cancer. J Pain Symptom Manage. 2014 Dec;48(6):1160-7.

Kiss N, Isenring E, Gough K, Krishnasamy M. The prevalence of weight loss during (chemo)radiotherpay treatment for lung cancer and associated patient- and treatment-related factors. Clin Nutr. 2014 Dec;33(6):1074-80.

Kiss N, Krishnasamy M, Everitt S, Gough K, Duffy M, Isenring E. Dosimetric factors associated with weight loss during (chemo)radiotherapy treatment for lung cancer. Eur J Clin Nutr. 2014 Dec;68(12):1309-14.

Chasen M, Bhargava R, Hirschman S. Immunomodulatory agents for the treatment of cachexia. Curr Opin Support Palliat Care. 2014 Dec;8(4):328-33.

Hundsberger T, Omlin A, Haegele-Link S, Vehoff J, Strasser F. Autonomic dysfunction in cancer cachexia coincides with large fiber polyneuropathy. J Pain Symptom Manage. 2014 Oct;48(4):611-8.e1.

Blum D, Koeberle D, Omlin A, Walker J, Von Moos R, Mingrone W, deWolf-Linder S, Hayoz S, Kaasa S, Strasser F, Ribi K. Feasibility and acceptance of electronic monitoring of symptoms and syndromes using a handheld computer in patients with advanced cancer in daily oncology practice. Support Care Cancer. 2014 Sep;22(9):2425-34.

Balstad TR, Solheim TS, Strasser F, Kaasa S, Bye A. Dietary treatment of weight loss in patients with advanced cancer and cachexia: a systematic literature review. Crit Rev Oncol Hematol. 2014 Aug;91(2):210-21. Erratum in: Crit Rev Oncol Hematol. 2015 Apr;94(1):146-8.

Aapro M, Arends J, Bozzetti F, Fearon K, Grunberg SM, Herrstedt J, Hopkinson J, Jacquelin-Ravel N, Jatoi A, Kaasa S, Strasser F. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann Oncol. 2014 Aug;25(8):1492-9.

Abbott J, Teleni L, McKavanagh D, Watson J, McCarthy A, Isenring E. A ovel, automated nutrition screening system as a predictor of nutritional risk in an oncology day treatment unit (ODTU). Support Care Cancer. 2014 Aug;22(8):2107-12.

Blum D, Stene GB, Solheim TS, Fayers P, Hjermstad MJ, Baracos VE, Fearon K, Strasser F, Kaasa S; Euro-Impact. Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model--a study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol. 2014 Aug;25(8):1635-42

Healy, E., Yaxley, A., Isenring, E., Bannerman, E., & Miller, M. (2014). Ability of existing malnutrition screening tools to identify risk of starvation, sarcopenia and cachexia: A systematic review. E-SPEN Journal, 2014 9(3).


Please contact the Study Group Chairs above with your questions.
MASCC Study Group Coordinator, Don Gubitosa